Indian Ranbaxy accused of falsifying the results of the testing of medicines

25.02.2009

U.S. market regulators have accused the largest Indian pharmaceutical company Ranbaxy Laboratories in the falsification of test results of some of its generic drugs, the Associated Press.

The U.S. administration to control the quality of food and drugs, FDA, intends to suspend consideration of admission to the market any new medicines produced by Ranbaxy Laboratories, said officials.

Regulators have noted that some drugs already are on the market. Despite the apparent false data, they do not have evidence of the safety of drugs for life and recommend that patients continue to receive them.

FDA said this just months after the U.S. borders have been closed for more than 30 generic drugs Ranbaxy, after detecting problems with quality at two factories of the company.